Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy

The outcomes for patients with chronic myeloid leukemia have improved dramatically with the development and availability of BCR–ABL1 tyrosine kinase inhibitors (TKIs) over the past decade. TKI therapy has a superior safety profile compared with the previous standard of care, interferon-α, and most a...

Descripción completa

Detalles Bibliográficos
Autor principal: DeAngelo, D J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483619/
https://www.ncbi.nlm.nih.gov/pubmed/23085780
http://dx.doi.org/10.1038/bcj.2012.30

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483619/
https://www.ncbi.nlm.nih.gov/pubmed/23085780
http://dx.doi.org/10.1038/bcj.2012.30

Ejemplares similares